Clinical Trials Directory

Trials / Completed

CompletedNCT03177850

Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Respiratory Disease at Altitude

Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Chronic Obstructive Pulmonary Disease at Altitude, Assessed by Respiratory Polygraphy: A Randomized, Placebo-controlled, Double-blind Parallel Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
185 (actual)
Sponsor
University of Zurich · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

In this trial, the investigators will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on sleep related breathing disturbances at altitude in patients with COPD.

Detailed description

This is a randomized, placebo-controlled, double-blind parallel trial evaluating the effect of acetazolamide (375 mg per day) vs. placebo on sleep related breathing disturbances in lowlanders with chronic obstructive pulmonary disease travelling to altitude. Participants living in the Bishkek area, Kyrgyzstan (760m), will be transferred by car within 4h to the Tuja Ashu high altitude clinic (3200 m), and stay there for 2 days. Acetazolamide 375mg/day (or placebo), will be administered 24 hours before departure at 760 m and during the stay at altitude. Outcomes will be assessed during the stay at 3200 m. Sleep related breathing disturbances will be evaluated by respiratory polygraphy. An interim analysis will be carried out when 90 patients will have completed the study or after the first year. The Peto's method will be used to correct the P-values.

Conditions

Interventions

TypeNameDescription
DRUGACETAZOLAMIDE oral capsuleAdministration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
DRUGPlacebo oral capsuleAdministration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m

Timeline

Start date
2017-05-24
Primary completion
2018-08-02
Completion
2018-08-02
First posted
2017-06-06
Last updated
2019-01-29

Locations

1 site across 1 country: Kyrgyzstan

Source: ClinicalTrials.gov record NCT03177850. Inclusion in this directory is not an endorsement.